AGA-2115

N/A

Report date: 2026/04/30 20:00:20
First In Class

Base Information

Drug NameAGA-2115
Drug Alias NameAGA-2115AGA2115
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionSclerostin inhibitorsDickkopf-related protein 1 inhibitors
TargetsSclerostinDickkopf-related protein 1
Therapy Area/IndicationsOsteogenesis Imperfecta
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAngitia Biopharmaceuticals (Guangzhou) Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAngitia Incorporated LtdAngitia Biopharmaceuticals (Guangzhou) Ltd
Inactive CompaniesN/A
Active IndicationsOsteogenesis Imperfecta
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank